Figure 4. Incidence of All-Grade Hypophysitis During Treatment With Different Immune Checkpoint Inhibitor Regimens^a.

Incidence rates are represented by boxes and whiskers indicate binomial exact 95% CIs. Model results are shown for each class of immunotherapy as a polygon using the fitted value and 95% prediction interval. Combination indicates nivolumab plus ipilimumab; CTLA-4, cytotoxic T-lymphocyte associated protein 4; PD-1, programmed cell death-1; and RE MODEL, random effects model.

^aThis analysis was restricted to melanoma-specific studies.

^bIncludes the number of patients eligible for safety analysis.